Literature DB >> 33707858

The Journey of Primary Myelofibrosis to Splenic Marginal Zone Lymphoma on the Wheels of Ruxolitinib.

Jasmita Dass1, Sabina Langer1, Jyoti Kotwal1, Nitin Gupta2.   

Abstract

Entities:  

Year:  2020        PMID: 33707858      PMCID: PMC7900293          DOI: 10.1007/s12288-020-01320-w

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


× No keyword cloud information.
  2 in total

1.  Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms.

Authors:  Elisa Rumi; Silvia Zibellini; Emanuela Boveri; Chiara Cavalloni; Roberta Riboni; Ilaria Carola Casetti; Michele Ciboddo; Chiara Trotti; Cristina Favaron; Daniela Pietra; Chiara Candido; Virginia Valeria Ferretti; Mario Cazzola; Luca Arcaini
Journal:  Am J Hematol       Date:  2019-05-01       Impact factor: 10.047

2.  Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Authors:  Edit Porpaczy; Sabrina Tripolt; Andrea Hoelbl-Kovacic; Bettina Gisslinger; Zsuzsanna Bago-Horvath; Emilio Casanova-Hevia; Emmanuelle Clappier; Thomas Decker; Sabine Fajmann; Daniela A Fux; Georg Greiner; Sinan Gueltekin; Gerwin Heller; Harald Herkner; Gregor Hoermann; Jean-Jacques Kiladjian; Thomas Kolbe; Christoph Kornauth; Maria-Theresa Krauth; Robert Kralovics; Leonhard Muellauer; Mathias Mueller; Michaela Prchal-Murphy; Eva Maria Putz; Emmanuel Raffoux; Ana-Iris Schiefer; Klaus Schmetterer; Christine Schneckenleithner; Ingrid Simonitsch-Klupp; Cathrin Skrabs; Wolfgang R Sperr; Philipp Bernhard Staber; Birgit Strobl; Peter Valent; Ulrich Jaeger; Heinz Gisslinger; Veronika Sexl
Journal:  Blood       Date:  2018-06-14       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.